匹多莫德联合阿奇霉素治疗小儿支原体肺炎疗效观察

目的观察匹多莫德联合阿奇霉素治疗小儿支原体肺炎的临床疗效。方法将68例小儿支原体肺炎患儿随机平均分为两组，对照组采用阿奇霉素序贯疗法治疗，治疗组在上述基础上加用匹多莫德口服治疗。观察治疗前后的临床症状、体征及外周血免疫细胞的变化。结果观察组发热、咳嗽及肺部哕音持续时间均明显低于对照组（P〈O．05），临床总有效率达97．1％，显著高于对照组的85.3％（P〈0．01）。观察组在治疗2个月后，血液CD3、CD4细胞数、CD4／CD8比值均明显高于治疗前（P〈O．05）。结论阿奇霉素联合匹多莫德治疗小儿支原体肺炎，临床症状、体征消失快，疗效显著，值得推广。

Effect of Pidotimod and Azithromycin in Treatment of Children Mycoplasma Pneumonia

Objective To observe effect of pidotimod and azithromycin in treatment of children patients with mycoplasma pneumonia. Methods 68 children with mycoplasma pneumonia were randomly divided into two groups. Patients in control group were treated by azithromycin sequential therapy. Patients in observer group were added in pidotimod oral treatment based on the above therapy. Clinical symptoms,signs and changes in peripheral blood immune cells were observed in all patients. Results Duration of fever,cough and pulmonary rales were significantly shorter in the observer group than that in the control group （P〈0.05）. Clinical total effective rate was 97.1%,which was significantly higher than the 85.3% of control group （P〈0.01）,blood CD3,CD4 cells,CD4/CD8 ratio in observer group after 2 months of treatment were significantly higher than before treatment （P〈0.05）. Conclusion In treatment of mycoplasma pneumonia with azithromycin and pidotimod,the clinical symptoms and signs disappear quickly,and the effect is satisfactory, which is worthy of promoting.